Study finds current prostate cancer screening guidelines may miss early-stage cancers in transgender women on hormone therapy due to lowered PSA levels.

A new study by Cedars-Sinai Cancer investigators reveals that current prostate cancer screening guidelines may miss early-stage cancers in transgender women on hormone therapy. Estrogen, often used in gender-affirming care, lowers PSA levels, potentially elevating the 'normal' threshold for detection. The study published in JAMA aims to determine typical PSA values for transgender women to improve screening methods.